Type II diabetes is characterized by increased oxidative stress, endothelial dysfunction and hypertension. We investigated whether short-term treatment with oral vitamin C reduces oxidative stress and improves endothelial function and blood pressure in subjects with Type II diabetes. Subjects (n l 35) received vitamin C (1.5 g daily in three doses) or matching placebo for 3 weeks in a randomized, double-blind, parallel-group design. Plasma concentrations of 8-epiprostaglandin F 2α (8-epi-PGF 2α ), a non-enzymically derived oxidation product of arachidonic acid, were used as a marker of oxidative stress. Endothelial function was assessed by measuring forearm blood flow responses to brachial artery infusion of the endothelium-dependent vasodilator acetylcholine (with nitroprusside as an endothelium-independent control) and by the pulse wave responses to systemic albuterol (endothelium-dependent vasodilator) and glyceryl trinitrate (endothelium-independent vasodilator). Plasma concentrations of vitamin C increased from 58p6 to 122p10 µmol/l after vitamin C, but 8-epi-PGF 2α levels (baseline, 95p4 pg/l ; after treatment, 99p5 pg/l), blood pressure (baseline, 141p5/80p2 mmHg ; after treatment, 141p5/81p3 mmHg) and endothelial function, as assessed by the systemic vasodilator response to albuterol and by the forearm blood flow response to acetylcholine, were not significantly different from baseline or placebo. Thus treatment with vitamin C (1.5 g daily) for 3 weeks does not significantly improve oxidative stress, blood pressure or endothelial function in patients with Type II diabetes.
INTRODUCTION
Cardiovascular morbidity and mortality represent a major challenge in patients with Type II diabetes [1] . Macrovascular disease, unlike microvascular disease, is not associated with a clear threshold of glycaemia below which cardiovascular risk is reduced. By contrast, aggressive blood pressure control and lipid lowering can substantially reduce myocardial infarction and stroke in subjects with Type II diabetes [2] . Despite such measures, cardiovascular mortality remains excessive in these patients.
Endothelial dysfunction and lipid peroxidation are key events in the initiation, progression and rupture of atheromatous plaque [3] . Lipid peroxidation results from increased oxidative stress, and there is accumulating evidence that this also accounts for endothelial dysfunction [4] . Type II diabetes is associated with increased oxidative stress [5] [6] [7] . This probably results both from excess generation of reactive oxygen species from a number of sources and from decreased enzymic and nonenzymic antioxidant defences [5] . Supplementation with antioxidants is therefore an attractive potential therapy. While vitamin E may be effective in preventing lipid peroxidation [8] , it has been reported not to improve endothelial function in subjects with Type II diabetes [9] or ischaemic heart disease [10, 11] , and in animal models may even impair endothelial function [8] . In contrast, acute intra-arterial administration of vitamin C improves endothelial function in subjects with Type II diabetes [12] . It also reduces the susceptibility of low-density lipoprotein (LDL) to oxidation [13] , decreases lipid peroxidation in smokers [14] and may lower blood pressure [15] . It is possible that a water-soluble antioxidant such as vitamin C, which is capable of scavenging superoxide anions
, is more effective than vitamin E in both protecting endothelium-derived nitric oxide and preventing lipid peroxidation. The object of the present study was to determine whether short-term oral administration of vitamin C reduces oxidative stress, improves endothelial function and lowers blood pressure in patients with uncomplicated Type II diabetes.
METHODS

Subjects
Patients with uncomplicated Type II diabetes (n l 35) controlled by diet or oral hypoglycaemic drugs were Table 1 Baseline characteristics of subjects ACE, angiotensin-converting enzyme. Values are meanspS.E.M., except for triacylglycerols, which are given as median (range). Significance of differences : *P 0n05 compared with placebo group.
Parameter
Placebo group (n l 17) Vitamin C group (n l 18) 
Study protocol
The study design was a randomized, parallel-group, double-blind, placebo-controlled comparison of vitamin C (500 mg, three times daily) with placebo for 3 weeks. Subjects attended a temperature-controlled clinical laboratory on two study days 3 weeks apart. On each of the two study days, patients attended after a fasting period, and blood was taken for the determination of levels of 8-epi-prostaglandin F # α (8-epi-PGF # α ) and biochemistry as described below. Blood pressure was measured after supine rest for 30 min. Three measurements separated by 5 min intervals were taken in the right arm using an automated measuring device (Dynamap, Critikon, TX, U.S.A.) and appropriate sized cuff. Patients then had endothelial function assessed in the peripheral systemic vasculature and (in a subset of 16 subjects ; eight in each group) in the forearm vasculature (see below).
Biochemical measurements
Total plasma (free plus esterified) 8-epi-PGF # α was measured by gas chromatography\negative-ion MS using deuterated PGF # α as an internal standard [6] . Vitamin C was measured using HPLC [16] . Serum total cholesterol, triacylglycerols, high-density lipoprotein (HDL)-cholesterol and glucose were measured using standard enzymic methods.
Endothelial function
Endothelium-dependent and -independent vasodilation of the systemic circulation was assessed by measuring the digital volume pulse (DVP) wave response to the systemic administration of the endothelium-dependent β # -agonist albuterol (salbutamol) and the nitric oxide donor glyceryl trinitrate (GTN), as previously described [7, 17] . Briefly, this method provides a sensitive means for detecting vasodilation of small arteries and hence reduced pressure wave reflection by measuring changes in the contour of the DVP. The DVP was obtained using a photoplethysmograph (Micro Medical, Gillingham, Kent, U.K.), and the height of the late systolic\early diastolic portion of the DVP was expressed as a percentage of the amplitude of the DVP to give the reflection index (RI DVP ) [7] . Following a 15 min period to establish basal measurements of RI DVP , the change in RI DVP (∆RI DVP ) in response to GTN (500 mg ; 3 min sublingually) was determined. After a further period of 25 min, after which RI DVP had returned to baseline, the response to albuterol (400 µg via inhalation through a spacer device) was determined.
In a subset of 16 subjects, endothelial function was also assessed by determining forearm blood flow responses to the brachial artery administration of acetylcholine (ACh ; endothelium-dependent vasodilator) and nitroprusside (NP ; endothelium-independent, NO donor). The brachial artery was cannulated with a 27 gauge needle using 1 ml of 1 % lidocaine local anaesthesia. Blood flow was measured by venous occlusion strain gauge plethysmography [18] using electrically calibrated strain gauges [19] during infusion of 0.9 % saline or drugs dissolved in saline at 1.0 ml\min. Following determination of basal flow, blood flow was measured during the infusion of three cumulative doses (7.5, 15 and 30 µg\min) of ACh (Coopervision, Southampton, U.K.) and, after blood flow had returned to baseline, of NP (1, 3 and 10 µg\min ; Roche, Basle, Switzerland). Each dose was infused for 6 min, with blood flow (mean of five venous occlusions) being measured during the last 2 min of each infusion period.
Statistical analysis and power calculations
Data are summarized as meanspS.E.M. Differences in baseline characteristics between the placebo and vitamin C groups were sought using χ# and Student's unpaired t test. Two-way ANOVA was used to test for differences between vitamin C-and placebo-treated groups in the change from baseline in the main outcome measures : 8-epi-PGF # α , blood pressure, ∆RI DVP in response to albuterol\GTN and forearm blood flow response to ACh\NP. When a difference between groups was significant, a paired t test was used to determine whether the change from baseline in each group was significant. All tests were two-tailed. P 0n05 was taken as significant. A sample size of n 34 (n 16 in each group) was estimated to give greater than 90 % power to detect changes in diastolic blood pressure, 8-epi-PGF # α and ∆RI DVP in response to albuterol of greater than 4 mmHg, 40 pg\ml and 4 % respectively.
RESULTS
Following supplementation with vitamin C, plasma concentrations of ascorbate increased from 58p6 µmol\l at baseline to 122p10 µmol\l (P 0.01 ; Table 2 ). Total cholesterol, triacylglycerols, HDL-and LDL-cholesterol, fasting glucose, and plasma concentrations of 8-epi-PGF # α remained similar in the placebo-and vitamin Ctreated groups. Blood pressure and responses of the DVP to albuterol and GTN were similar in the placebo and vitamin C groups ( Table 2 ). The 95 % confidence intervals for decreases in blood pressure following vitamin C were 11 and 4 mmHg for systolic and diastolic blood pressure respectively. The 95 % confidence interval for an increase in ∆RI DVP in response to albuterol following vitamin C was 4 %. Forearm blood flow responses to brachial artery infusion of ACh and NP (Table 2 ) also remained similar before and after supplementation in both groups.
DISCUSSION
Despite resulting in a doubling of the plasma concentration of vitamin C, vitamin C treatment at the dose and for the duration used in the present study did not lower oxidative stress, as assessed by plasma concentrations of the isoprostane 8-epi-PGF # α . This finding is unexpected, because Type II diabetes is well recognized to be associated with increased oxidative stress, plasma concentrations of 8-epi-PGF # α are elevated in Type II diabetes [6, 7] , and vitamin C lowers 8-epi-PGF # α levels in other conditions associated with oxidative stress. 8-Epi-PGF # α is elevated in smokers, and treatment with a similar dose of vitamin C for a similar duration as used in the present study lowers urinary 8-epi-PGF # α [14] .
Antioxidant treatment with vitamin E lowers 8-epi-PGF # α in animal models of diabetes [8] , and treatment for [20] . It is notable that baseline vitamin C concentrations were within the accepted normal range [22] in our subjects, and it is possible that supplementation with vitamin C is only effective in reducing plasma [21] . The acute effect of vitamin C in improving endothelial function in patients with Type II diabetes [12] has been attributed to this mechanism. In the present study we observed no beneficial effect of oral vitamin C on the endothelium-dependent forearm vasodilator response to the intra-brachial artery infusion of ACh or pulse wave reflection in response to systemic administration of the endothelium-dependent β # -agonist albuterol. We cannot exclude a small effect of vitamin C on endothelial function, but the 95 % confidence interval in the present study excluded a difference similar to that observed previously between non-diabetic and diabetic subjects [7, 17] . The discrepancy between our finding and the effects seen in the acute intra-arterial study of Ting et al. [12] may be explained by dose. Local infusion of vitamin C would have produced concentrations (estimated from the rate of infusion and forearm blood flow) exceeding 1 mmol\l. This compares with plasma levels of 122 µmol\l in our present study after oral supplementation. The much higher concentrations in the intraarterial study may have been effective at reversing oxidant stresses. Acute administration of oral vitamin C does improve endothelial function in smokers [22] and patients with ischaemic heart disease [23] , demonstrating that beneficial effects of oral vitamin C are potentially attainable. It is possible, however, that the mechanism of this acute effect does not involve an antioxidant effect [24] . It is notable that, in smokers, endothelial function is improved by acute, but not chronic, administration of vitamin C [25] . The lack of an effect of oral vitamin C in patients with Type II diabetes may relate to the source of the oxidant stress. Vitamin C is effective in scavenging extracellular O # generation in diabetes than in other conditions associated with increased oxidative stress, particularly smoking. It is unlikely that treatment for a longer period would further substantially increase intracellular concentrations of vitamin C since, at lower daily doses of 100-200 mg, plasma concentrations plateau after 3 weeks, saturating intracellular ascorbic acid levels [28] . We cannot, however, exclude the possibility that a longer duration of treatment with a different dose of vitamin C may be effective in lowering oxidative stress and\or improving endothelial function. It is also possible that high doses may have an adverse effect : there is evidence that high concentrations may cause oxidative damage to DNA [29] and may indeed lower NO bioactivity [30] .
Vitamin C alone and as part of combination antioxidant therapy at doses similar to those used in the present study has been shown to lower blood pressure in patients with essential hypertension [15, 31] . In hypertensive subjects, the effects of vitamin C are similar to those of a small dose of a thiazide diuretic. The mechanism has been ascribed to an increase in oxidative stress in essential hypertension. The lack of effect of vitamin C on blood pressure in the present study may be explained by relatively well-controlled blood pressure and\or concurrent antihypertensive treatment in our subjects. However, it is also consistent with the possibility that vitamin C does not lower oxidative stress in patients with Type II diabetes. We cannot exclude a small ( 4 mmHg diastolic) effect of vitamin C on blood pressure.
In conclusion, treatment with vitamin C (1.5 g daily) for 3 weeks produced no significant improvements in oxidative stress, blood pressure or endothelial function in patients with Type II diabetes.
